DOCSLIB.ORG

The 26Th Annual Dr. George Perez Research Colloquium Abstracts of Presentations Seton Hall University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The 26Th Annual Dr. George Perez Research Colloquium Abstracts of Presentations Seton Hall University Seton Hall University eRepository @ Seton Hall Petersheim Academic Exposition Petersheim Academic Exposition 4-24-2015 The 26th Annual Dr. George Perez Research Colloquium Abstracts of Presentations Seton Hall University Follow this and additional works at: https://scholarship.shu.edu/petersheim-exposition THE 26TH ANNUAL DR. GEORGE PEREZ RESEARCH COLLOQUIUM ABSTRACTS OF PRESENTATIONS PRESENTED IN CONJUNCTION WITH THE SETON HALL UNIVERSITY PETERSHEIM ACADEMIC EXPOSITION 24 APRIL 2015 Cover Patients with diarrhea and abdominal pain N=417 Excluded (insufficient data) N=48 EIA for GDH Ag mu taneous y Negative Positive N=149 N=220 EIA Toxin A/B Positive EIA Negative EIA Toxin A/B Toxin A/B N=145 PCR for toxin B gene Positive Negative N=0 Toxigenic (EIA +) EIA (–) C. difficile C. difficile MDAdvantNow you know…age WE PROVIDE VALUE BEYOND INSURANCE. At MDAdvantage®, our mission is to be a haven of safety, stability and strength for New Jersey healthcare. We advocate for physicians and actively support the practice of medicine in New Jersey. We have earned a reputation for integrity, responsiveness and decisive management, and stand prepared to assist healthcare providers in facing the challenges associated with today’s changing healthcare environment. Want to know more? Visit www.MDAdvantageonline.com 100 Franklin Corner Road, Lawrenceville NJ 08648-2104 888-355-5551 Exclusive Sponsor of the Perez Research Colloquium 24 April 2015 Dear Colleagues and Students: It is my distinct pleasure to greet you as you attend the 26th Annual Dr. George Perez Research Colloquium of the School of Health and Medical Sciences. Since 1990, the Research Colloquium has been the vehicle for our faculty, residents, fellows and health sciences students to present the results of the scholarly pursuits in which they have been engaged. We also enjoy the participation of some of the medical students at the healthcare institutions that comprise our graduate medical education consortium. For this year’s Research Colloquium, we are also happy to be joined by our colleagues from the Seton Hall College of Nursing and Seton Hall’s newest partner in the realm of academic medicine, Hackensack University Medical Center. We welcome, also, our keynote speaker, Danielle Ofri, MD, PhD. Dr. Ofri is an essayist, editor and practicing internist at Bellevue Hospital in New York City. Dr. Ofri’s talk will deal with ways and means to reinvigorate members of the healthcare team who, all too often, are burdened by the many challenges they face on a daily basis. Once again our program is being sponsored by MDAdvantage Insurance Company of New Jersey, a leading provider of medical professional liability insurance in New Jersey. As a company committed to investing in the future of New Jersey’s healthcare system, MDAdvantage has been an ongoing partner in supporting medical education and encouraging the medical students, residents and young physicians of our state to realize their greatest potential. I would also like to take this opportunity to thank my fellow faculty members who assisted in the preparation for today’s event. I would also be remiss if I didn’t recognize the many individuals from Seton Hall’s administrative staff for making the Research Colloquium a success. Most of all, however, I thank the presenters and their co-authors for sharing the results of their studies with us. Have a wonderful and productive day. Collegially yours, Vincent A. DeBari, PhD Professor of Medicine and Director of Research School of Health and Medical Sciences 400 South Orange Avenue • South Orange, New Jersey 07079 A HOME FOR THE MIND, THE HEART AND THE SPIRIT 24 April 2015 Dear Colleagues and Students: Welcome to the School of Health and Medical Sciences’ (SHMS) 26th Annual Dr. George Perez Research Colloquium, presented in conjunction with the Seton Hall University Petersheim Academic Exposition. I am pleased that you could join us, as it is the collaborative exchange of knowledge that makes research and scholarly inquiry exciting. Our annual Research Colloquium provides the venue to demonstrate SHMS’ commitment to Interprofessional Education (IPE). The Research Colloquium showcases the leading research by the medical faculty, residents and fellows from our Division of Medical Residencies and Fellowships, as well as faculty and students from our Division of Health Sciences. Students and faculty from the University’s Department of Biological Sciences also have been regular participants, and I am pleased to welcome the College of Nursing to this year’s event. In recognition of Seton Hall’s recently announced partnership with Hackensack University Health Network (HUHN) to create a new school of medicine, I am pleased to welcome our colleagues from HUHN to the Research Colloquium. This new partnership, coupled with our ongoing legacy partnerships with the other hospitals where our medical residency and fellowship programs are based, brings innumerable opportunities for collaboration. On behalf of all Research Colloquium participants, I extend my sincere thanks to Vincent DeBari, PhD, Professor of Medicine and Director of Research, for bringing together the nearly 300 platform and poster presentations that we will experience today. I also would like to thank the Petersheim Steering Committee, led by Jose Lopez, PhD, and Anthony Troha, PhD, co-chairs and assistant professors in the Seton Hall Department of Physics, for welcoming our continued participation in the Petersheim Academic Exposition. To all of today’s presenters – thank you! Your dedication and scholarship are critical to advancing our research mission. Cordially, Brian B. Shulman, PhD, CCC-SLP, ASHA Fellow, BCS-CL, FASAHP Dean and Professor of Speech-Language Pathology School of Health and Medical Sciences 400 South Orange Avenue • South Orange, New Jersey 07079 A HOME FOR THE MIND, THE HEART AND THE SPIRIT PROGRAM 7:30 a.m. – 8 a.m. .......................................Registration and Continental Breakfast 8 a.m. – 1 p.m. ................................................................................... Poster Session Basic Medical Sciences (BMS) Clinical Investigation (CI), except for Oral Presentations, listed on the following page Clinical Vignettes (CV) Health Sciences Research (HSR) Research in Progress (IP) NOTE: Posters must be removed at 1:00 p.m. 8:30 a.m. – 10 a.m. .................................................................... Oral Presentations I 10:15 a.m. – 11 a.m. .......................................................................... Invited Speaker Danielle Ofri, MD, PhD “Surviving Medicine in the 21st Century” 11 a.m. – 11:30 a.m. ...................................Intermission and Light Refreshments 11:30 a.m. – 1 p.m. ............................................................... Oral Presentations II ORAL PRESENTATIONS SESSION I: 8:30 - 10 a.m. CI 02 Platelet Reactivity Unit in Predicting Risk of Bleeding in Patients Undergoing Coronary Artery Bypass Graft Surgery Altheeb, Z.F.; Isbitan, A.; Shabiah, M.; Hamdan, A.; DeBari, V.; Shamoon, F. CI 09 The Characteristics of Rebound Nystagmus in Patients and Normal Subjects Bhatt, S.H; Patel, K.; Rosenberg, M.L. CI 18 A Comparison of Transient Elastography (Fibroscan) and The APRI Score, Two Non-Invasive Tests for Liver Fibrosis Staging in HIV/HCV Co-Infected Patients Dazley, J.; Sison, R.; Shukla, P.; Galang, H.; Szabela, E.; Slim, J.; Adebara, A. CI 33 Value of Neutrophil to Lymphocyte Ratio as a Predictor of Mortality in Patients Undergoing Aortic Valve Replacement Habib, M.; Thawabi, M.; Habib, H.; Hawatmeh, A.; Elkhalili, W.; Shamoon, F.; Zaher, M. CI 36 Utility of Brain Natriuretic Peptide Assay in Patients Presenting with Syncope to the Emergency Department Isbitan, A.A.; Altheeb, Z.F.; Patel, K.; Al-Nahar, Y.; Hamdan, A.; Shamoon, F. INTERMISSION: 11 - 11:30 a.m. SESSION II: 11:30 a.m. - 1 p.m. CI 38 The Incident Trends, Epidemiology, Mortality, and Economics Evaluation of Vertebral Osteomyelitis in the United States: A Nationwide Inpatient Database Study of 283,022 Cases from 1998 to 2010 Issa, K.; Patel, S.; Shafa. E.; Faloon, M.; Sinha, K.; Hwang, K.; Emami, A. CI 42 Comparison of Thyroid Stimulating Hormone Level and PR Interval in Hypothyroid Patients Being Treated with Levothyroxine Khaddash, I.; Altheeb, Z.; Shahla, L.; Gupta, R.; Sheth, V.; DeBari, V.; Shamoon, F. CI 67 Laboratory and Clinical Features of EIA Toxin-Positive and EIA Toxin-Negative Community-Acquired Clostridium Difficile Infection Patel, H.; Randhawa, J.; Nanavati, S.; Marton, R.; Baddoura, W.; DeBari, V. CI 68 Poor Left Atrial Function is associated with Reduced Left Ventricular Ejection Fraction in Hospitalized Patients Patel, H.; Ariyarajah, V.; Haft, J.; Goldfarb, I.; Bikkina, M.; Shamoon, F. CI 73 ST-Segment Elevation Myocardial Infarction in Octogenarians: 30-day Mortality and Peri-Procedural Complications Compared to Younger Adults Shah, P.; Mechineni, A.; Yamini, S.; Bajaj, S.; Virk, H.; DeBari, V.; Shamoon, F.; Bikkina, M. NOTE: Throughout this Abstracts of Presentation publication, research denoted with an asterisk (*) indicates that it will be presented orally and not via a poster. INVITED SpeaKer Danielle Ofri, MD, PhD Dr. Ofri writes regularly for the New York Times about medicine and the doctor-patient relationship. Her most recent book is What Doctors Feel: How Emotions Affect the Practice of Medicine (Beacon Press, 2014). Dr. Ofri is an internist at Bellevue Hospital in New York City, the oldest public hospital in the country, and an Associate Professor
Load more

Recommended publications
  • Defining Natural Antibodies
    PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5).
    [Show full text]
  • Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia
    Standing Council on Health Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition July 2012 Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition July 2012 Disclaimer: Important information about this document This document is not a clinical practice guideline. It intends only to provide information about criteria for accessing intravenous immunoglobulin funded under the National Blood Arrangements. Any advice relating to other forms of treatment relevant to the conditions in The Criteria for the clinical use of intravenous immunoglobulin in Australia (the Criteria) have not been subject to a systematic review and should not be relied upon to guide treatment. Patients and doctors should not use this document as a substitute for expert medical guidance and advice. The relevance and appropriateness of information in this document depends, amongst other things, on an accurate diagnosis, the severity of the condition being properly ascertained, the individual response to diagnostic tests and therapies, and other relevant circumstances in each case. The Criteria was first published in 2007 after a systematic review that was completed in mid-2006. Another systematic review, of a limited number of indications, was then undertaken in 2010-11 to update the Criteria. This review resulted in the addition of a small number of indications, removal of a small number of indications and a rewording of a limited number of indications. Inclusion of indications in the Criteria is based where possible upon systematic review of the evidence. In the absence of published evidence, information and access criteria are based on clinical advice provided to the development group by clinical colleges, clinical societies and individual experts.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases
    Journal of Clinical Medicine Article Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases Johannes Dorst 1,* , Frank Fillies 1, Jens Dreyhaupt 2 , Makbule Senel 1 and Hayrettin Tumani 1 1 Department of Neurology, University of Ulm, 89081 Ulm, Germany; frank.fi[email protected] (F.F.); [email protected] (M.S.); [email protected] (H.T.) 2 Institute for Epidemiology and Medical Biometry, University of Ulm, 89081 Ulm, Germany; [email protected] * Correspondence: [email protected] Received: 13 August 2020; Accepted: 3 September 2020; Published: 5 September 2020 Abstract: Plasma exchange (PE) and immunoadsorption (IA) are frequently used for treatment of various autoimmune-mediated neurological diseases, including multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain–Barré syndrome (GBS). Although both methods are generally regarded as well-tolerated treatment options, evidence for safety and tolerability is low for most indications and largely relies on small case series. In this study, we retrospectively analysed adverse events (AEs) and laboratory changes in 284 patients with various neurological indications who received either PE (n = 65, 113 cycles) or IA (n = 219, 435 cycles) between 2013 and 2020 in our Neurology department. One standard treatment cycle for PE as well as IA consisted of five treatments on five consecutive days. During every treatment, the 2.0–2.5-fold individual plasma volume (PV) was treated in IA, while in PE, the 0.7-fold individual PV was replaced by human albumin solution. Overall, both methods showed an excellent safety profile; no deaths of life-threatening adverse events were recorded.
    [Show full text]
  • Treatment of Donor-Specific Antibody-Mediated Graft Rejection by Immunochemotherapy, Third-Party DLI, Plasmapheresis and Immunoa
    Bone Marrow Transplantation (2015) 50, 613–614 © 2015 Macmillan Publishers Limited All rights reserved 0268-3369/15 www.nature.com/bmt LETTER TO THE EDITOR Treatment of donor-specific antibody-mediated graft rejection by immunochemotherapy, third-party DLI, plasmapheresis and immunoadsorption Bone Marrow Transplantation (2015) 50, 613–614; doi:10.1038/ B cells, we first administered immunochemotherapy according to bmt.2014.321; published online 26 January 2015 a modified fludarabine, cytarabine, rituximab (FCR) scheme (rituximab 3 × 375 mg/m2 days +27 to +30, cyclophosphamide 2 fl 2 fi 3 × 300 mg/m and udarabine 3 × 30 mg/m both days +30 to In allogenic SCT, patient-derived donor-speci c HLA antibody +32). Most prophylactic desensitization protocols used irradiated (DSA)-mediated graft rejection is a rare, but serious complication. 1 lymphocyte infusions (DLI) or platelet infusions from the original Gergis et al. recently described a new therapeutic approach to donor or infusion of surrogate platelets.2 In our patient, no DLI or reduce pre-existing DSA before allogeneic transplantation to donor platelets were available, as this donor was prepared for the enhance the likelihood of engraftment in 10 patients. They second donation. In this special situation, we took advantage of combined pretransplant extracorporeal antibody elimination by the fact that the haploidentical son carried the same mismatched plasmapheresis with immunochemotherapy (rituximab, bortezo- A2 antigen as the donor (Table 1). We hence isolated a total of mib and/or intravenous immunglobuline (i.v.IG)) and thereby 1.9 × 108 CD3+ lymphocytes/kg from the haploidentical son and achieved substantial reduction in DSA titers with sustained infused these cells after irradiation in three fractions on days +32 engraftment in nine patients.
    [Show full text]
  • Plasma Exchange Or Immunoadsorption in Demyelinating Diseases: a Meta-Analysis
    Journal of Clinical Medicine Article Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis Mark Lipphardt, Manuel Wallbach and Michael J. Koziolek * Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, D-37075 Goettingen, Germany; [email protected] (M.L.); [email protected] (M.W.) * Correspondence: [email protected]; Tel.: +49-55-1396-5751; Fax: +49-55-1396-5752 Received: 11 May 2020; Accepted: 18 May 2020; Published: 25 May 2020 Abstract: Multiple sclerosis (MS) is an inflammatory disease mainly affecting the central nervous system. In MS, abnormal immune mechanisms induce acute inflammation, demyelination, axonal loss, and the formation of central nervous system plaques. The long-term treatment involves options to modify the disease progression, whereas the treatment for the acute relapse has its focus in the administration of high-dose intravenous methylprednisolone (up to 1000 mg daily) over a period of three to five days as a first step. If symptoms of the acute relapse persist, it is defined as glucocorticosteroid-unresponsive, and immunomodulation by apheresis is recommended. However, several national and international guidelines have no uniform recommendations on using plasma exchange (PE) nor immunoadsorption (IA) in this case. A systematic review and meta-analysis was conducted, including observational studies or randomized controlled trials that investigated the effect of PE or IA on different courses of MS and neuromyelitis optica (NMO). One thousand, three hundred and eighty-three patients were included in the evaluation. Therapy response in relapsing-remitting MS and clinically isolated syndrome was 76.6% (95%CI 63.7–89.8%) in PE- and 80.6% (95%CI 69.3–91.8%) in IA-treated patients.
    [Show full text]
  • Basic Neuroimmunology
    02-Aug-19 Basic Neuroimmunology Metha Apiwattanakul MD. Neuroimmunology Unit Department of Neurology Prasat Neurological Institute August 2nd , 2019 Outline • Essential immunology (innate + adaptive) for neurologist with clinical correlation to neurological disease • Immunity control: tolerance and immune-homeostasis • General concept of autoimmune disease • Pathophysiology of immune mediated disease in CNS & PNS • General concept for treatment & monitor patients with immune mediated disease 1 02-Aug-19 Innate system works first & fast to recognize foreign subjects How this system KNOWS self Innate immune system & non-self?? Innate immune • Initial response to infection or damage • Macrophage, dendritic cells, neutrophils, NK cell are triggered by damaged or dying cell • Host cell damage cellular debris DAMPs (damage- associated molecule patterns • Pathogen attacks cause common molecular structures on cell surface PAMPs (pathogen associated molecular pattern) • Both DAMPs & PAMPs are recognized by “pattern-recognition receptors” such as TLR, NLR, NK receptor • Complement activation 2 02-Aug-19 Innate mechanism Pattern recognition mechanism Complement mechanism by PRR (TLR, NLR, NK rec) Complement system Eculizumab: drug that binds to C5 and inhibit the cleavage of C5 by C5 convertase 3 02-Aug-19 Innate immunity in CNS • Microglia: phagocytose & produce trophic factors, chemokines, cytokines, complement protein, ROS, NO • Play an important role in neurodegenerative disease (ALS, PD, AD) Adaptive immune response 1. Specificity 2. Diversity:
    [Show full text]
  • Conference Abstract Book
    45th EDTNA/ERCA International Conference September 17–20, 2016 The Valencia Conference Centre Valencia, Spain Conference Theme: Quality versus Cost Sustainable Renal Care Abstract Book 45th EDTNA/ERCA International Conference September 17–20, 2016 Valencia, Spain Acknowledgements We would like to express our appreciation for the valuable support participating at our 45th EDTNA/ERCA International Conference in Valencia, September 17-20, 2016. P artners’ support, involvement and advice are greatly appreciated and the success would not be possible without the fantastic collaboration we have. Thank You! Publisher: EDTNA/ERCA, European Dialysis and Transplant Nurses Association/European Renal Care Association, Pilatusstrasse 35, CH-6003 Lucerne, Switzerland Design and typography: GUARANT International spol. s r.o. ISBN: 978-84-617-4358-2 2 45th EDTNA/ERCA International Conference September 17–20, 2016 Valencia, Spain Contents ( ) FOREWORD 6 COMMITTEES 8 SPEAKERS 10 SCIENTIFIC PROGRAMME 12 PROGRAMME AT A GLANCE Saturday, September 17, 2016 13 Sunday, September 18, 2016 14 Monday, September 19, 2016 19 Tuesday, September 20, 2016 23 ORAL PRESENTATIONS Saturday, September 17, 2016 S 01 – Plenary Session 24 S 02 – Opening Ceremony 24 Sunday, September 18, 2016 S 03 – Fresenius Medical Care - Crossing Borders, Setting Standards: Embedding a Culture of Training and Education 25 S 04 – Masterclass – Transplantation 26 S 05 – Peritoneal Dialysis 28 S 06 – Ethical Issues in renal care 33 S 07 – Challenge of multimorbitity 38 S 08 – Masterclass - ‚Who
    [Show full text]
  • Guidelines for Antibody Incompatible Transplantation
    The Voice of Transplantation in the UK Guidelines for Antibody Incompatible Transplantation Third Edition Compiled by a Working Party of The British Transplantation Society Draft posted on www.bts.org.uk December 2015 British Transplantation Society Guidelines © British Transplantation Society www.bts.org.uk Contents 1 INTRODUCTION 4 1.1 The Need for Guidelines 4 1.2 Process of Writing and Methodology 4 1.3 Guideline Development Group 5 1.4 Declarations of Interest 8 1.5 Grading of Recommendations 9 1.6 Abbreviations 10 1.7 Disclaimer 11 2 EXECUTIVE SUMMARY OF RECOMMENDATIONS 13 3 TRANSPLANT UNITS AND LABORATORIES 18 3.1 Introduction 19 3.2 Definition of Antibody Incompatible Transplantation 19 3.3 Registry of Antibody Incompatible Transplantation 22 3.4 Histocompatibility and Immunogenetics Laboratories 22 3.5 Transplant Units 26 4 SELECTION, RISK ASSESSMENT AND MAKING CHOICES 29 4.1 Informed Choices and Kidney Sharing 29 4.2 Outcomes and Risk factors for HLAi 31 4.3 Outcomes and Risk Factors for ABOi 34 5 CONDITIONING TREATMENT BEFORE TRANSPLANTATION 38 5.1 Strategies for Conditioning Therapy 38 5.2 Extracorporeal Antibody Removal Therapy 39 5.3 Pre-transplant Drug Therapy 40 6 INITIAL THERAPY AND MONITORING IN THE EARLY POST- 44 TRANSPLANT PHASE 6.1 Occurrence of Acute AMR and Monitoring 44 6.2 Choice of Immunosuppression in HLAi 45 6.3 Choice of Immunosuppression in ABOi 45 7 DIAGNOSIS AND TREATMENT OF ACUTE ANTIBODY MEDIATED 49 REJECTION 7.1 Introduction and Diagnosis 49 7.2 Treatment of Acute AMR 51 7.3 Extracorporeal Antibody Removal
    [Show full text]
  • Guidelines on the Use of Therapeutic Apheresis in Clinical Practice
    Journal of Clinical Apheresis 25:83–177 (2010) Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis Zbigniew M. Szczepiorkowski,1*y Jeffrey L. Winters,2* Nicholas Bandarenko,3* Haewon C. Kim,4* Michael L. Linenberger,5* Marisa B. Marques,6* Ravindra Sarode,7* Joseph Schwartz,8* Robert Weinstein,9* and Beth H. Shaz10* 1Transfusion Medicine Service, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 2Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota 3Transfusion Service, Department of Pathology, Duke University, Durham, North Carolina 4Apheresis Service, Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 5The Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington 6Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 7Transfusion Medicine and Coagulation Laboratory, University of Texas, Southwestern Medical Center, Dallas, Texas 8Transfusion Medicine and Cellular Therapy Section, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York 9Division of Transfusion Medicine, Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 10Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia The
    [Show full text]
  • Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies
    Journal of Clinical Medicine Article Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies Alexander J. Davies 1 , Janev Fehmi 1, Makbule Senel 2 , Hayrettin Tumani 2, 2, 1, , Johannes Dorst y and Simon Rinaldi * y 1 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK; [email protected] (A.J.D.); [email protected] (J.F.) 2 Department of Neurology, University of Ulm, 89081 Ulm, Germany; [email protected] (M.S.); [email protected] (H.T.); [email protected] (J.D.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 19 May 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: The inflammatory neuropathies are disabling conditions with diverse immunological mechanisms. In some, a pathogenic role for immunoglobulin G (IgG)-class autoantibodies is increasingly appreciated, and immunoadsorption (IA) may therefore be a useful therapeutic option. We reviewed the use of and response to IA or plasma exchange (PLEx) in a cohort of 41 patients with nodal/paranodal antibodies identified from a total of 573 individuals with suspected inflammatory neuropathies during the course of routine diagnostic testing (PNAb cohort). 20 patients had been treated with PLEx and 4 with IA. Following a global but subjective evaluation by their treating clinicians, none of these patients were judged to have had a good response to either of these treatment modalities. Sequential serology of one PNAb+ case suggests prolonged suppression of antibody levels with frequent apheresis cycles or adjuvant therapies, may be required for effective treatment.
    [Show full text]
  • Policy Name: Therapeutic Apheresis (TA) - Plasmapheresis, Plasma Exchange Effective Date: 2/17/2020
    Medica Coverage Policy Policy Name: Therapeutic Apheresis (TA) - Plasmapheresis, Plasma Exchange Effective Date: 2/17/2020 Important Information - Please Read Before Using This Policy These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage. With respect to Medicare and Minnesota Health Care Programs, this policy will apply unless those programs require different coverage. Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica coverage policy may call the Medica Provider Service Center toll-free at 1-800-458-5512. Medica coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care and treatment. Coverage Policy EXTRACORPOREAL COLUMN IMMUNOADSORPTION APHERESIS Therapeutic apheresis (TA) employing extracorporeal immunoadsorption (ECI) is COVERED for the following indications: 1. Acute inflammatory demyelinating polyneuropathy (Guillain-Barre syndrome, acute), primary treatment 2. Chronic inflammatory demyelinating polyradioculoneuropathy (CIDP) 3. Cryoglobulinemia, severe/sumptomatic 4. Dilated idiopathic cardiomyopathy, NYHA II-IV 5. Encephalitis associated with N-methyl D-aspartate receptor antibodies 6. Focal segmental glomerulosclerosis, recurrent in kidney transplant 7. Multiple sclerosis, acute attack/relapse 8. Myasthenia gravis, acute/short term and long term treatment 9. Neuromyelitis optica spectrum disorders, acute attack or relapse (Devic’s syndrome) 10. Renal transplantation, ABO compatible a. Antibody-mediated rejection or desensitization, or desensitization in living donor 11.
    [Show full text]